Trial Profile
A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Ozanimod (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms RADIANCE
- Sponsors Celgene Corporation; Celgene International SARL; Receptos
- 29 Feb 2024 According to a Bristol-Myers Squibb media release, long-term disability progression in ozanimod-treated participants with relapsing multiple sclerosis from the SUNBEAM, RADIANCE, and DAYBREAK trials will be presented at the 9th annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 in West Palm Beach, Florida taking place February 29 to March 2.
- 13 Oct 2023 Results assessing the incidence and predictors of relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA) in RADIANCE and DAYBREAK (data cutoff: 1 Feb 2022) participants, presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis.
- 13 Oct 2023 Results assessing 3-month confirmed disability progression over 5-7 years of continuous ozanimod treatment in patients stratified by high or low base-line spinal cord area, whole brain volume, orthalamic volume in RADIANCE and DAYBREAK trials, presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis.